Cambridge, Massachusetts, United States The leading representative office of defined VC is situated in the Cambridge. The company was established in North America in United States. Johnson & Johnson Innovation u2013 JJDC appeared to be a CVC structure as part of the corporation.
The increased amount of exits for fund were in 2018. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. This Johnson & Johnson Innovation u2013 JJDC works on 23 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2019. The fund is generally included in 2-6 deals every year.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Johnson & Johnson Innovation u2013 JJDC, startups are often financed by Wildcat Capital Management, Johnson & Johnson Development Corporation, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are Wildcat Capital Management, Whittier Ventures, VSP Global. In the next rounds fund is usually obtained by dRx Capital, Lux Capital, Lightstone Ventures.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Memebox, Fusion Pharmaceuticals, X-Vax Technology We can highlight the next thriving fund investment areas, such as Pharmaceutical, Therapeutics. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.
Related Funds
| Fund Name | Location |
| Bank One | Chicago, Illinois, United States |
| Birk Venture | Norway, Oslo |
| Delta Dental | Illinois, Oak Brook, United States |
| Equilibrium Capital | California, San Francisco, United States |
| Frog Capital | England, London, United Kingdom |
| Harmony Medical | - |
| ICICI Prudential Mutual Fund | India, Maharashtra, Mumbai |
| Inlign Wealth | - |
| Ironside Ventures | Massachusetts, United States, West Newton |
| Macquarie Infrastructure Partners | Australia, New South Wales, Sydney |
| McDonnell Ventures | - |
| Peak Capital Partners | Provo, United States, Utah |
| Shenzhen Yizan Investment Management | China, Guangdong, Shenzhen |
| TR Capital | China, Hong Kong, Hong Kong Island |
| ULan Network | - |
| Upshift Partners | California, San Francisco, United States |
| VENTA GROUP | - |
| Venture Center | India, Maharashtra, Pune |
| Xinhu Holding | - |
| Yamanashi Chugin Management Consulting | Japan, Kofu, Yamanashi Prefecture |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Tempo Therapeutics | $12M | 15 Mar 2024 | San Diego, California, United States | ||
Asgard Therapeutics | $35M | 14 Mar 2024 | Lund, Skane Lan, Sweden | ||
Accent Therapeutics | $75M | 23 Jan 2024 | Lexington, Kentucky, United States | ||
Aro Biotherapeutics | $41M | 28 Nov 2023 | Philadelphia, Pennsylvania, United States | ||
On Target Laboratories | $30M | 16 Nov 2023 | Illinois, United States | ||
ROME Therapeutics | $72M | 12 Sep 2023 | Cambridge, Massachusetts, United States | ||
Rapport Therapeutics | $150M | 23 Aug 2023 | Boston, Massachusetts, United States | ||
CirCode | 15 Aug 2023 | Shanghai, Shanghai, China | |||
Astraveus | $19M | 27 Jun 2023 | Paris, Ile-de-France, France |
– Visus Therapeutics from Seattle develops innovative ophthalmic therapies to improve vision for people around the world.
– The company raised $20m in funding.
– The round was led by LSP in Amsterdam with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation -JJDC, Inc. and other inside investors.
– The new investment will be used to advance its clinical and commercial efforts for lead asset BRIMOCHOL under investigation for presbyopia as well as new research and development activities in its drug development pipeline.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Tempo Therapeutics | $12M | 15 Mar 2024 | San Diego, California, United States | ||
Asgard Therapeutics | $35M | 14 Mar 2024 | Lund, Skane Lan, Sweden | ||
Accent Therapeutics | $75M | 23 Jan 2024 | Lexington, Kentucky, United States | ||
Aro Biotherapeutics | $41M | 28 Nov 2023 | Philadelphia, Pennsylvania, United States | ||
On Target Laboratories | $30M | 16 Nov 2023 | Illinois, United States | ||
ROME Therapeutics | $72M | 12 Sep 2023 | Cambridge, Massachusetts, United States | ||
Rapport Therapeutics | $150M | 23 Aug 2023 | Boston, Massachusetts, United States | ||
CirCode | 15 Aug 2023 | Shanghai, Shanghai, China | |||
Astraveus | $19M | 27 Jun 2023 | Paris, Ile-de-France, France |
